Shares in Kenvue, the consumer health company spun off from Johnson & Johnson, have seen a notable decline following a significant legal development in the United States. A US appeals court has ruled to revive hundreds of lawsuits that allege a link between prenatal exposure to acetaminophen, the active ingredient in its popular pain reliever Tylenol, and the development of autism in children. This decision overturns a previous ruling by a lower court judge who had dismissed the cases, deeming the scientific evidence presented by the plaintiffs as unreliable.
The legal challenge centres on claims that mothers who used Tylenol during pregnancy unknowingly increased the risk of their children developing autism spectrum disorder. Plaintiffs argue that Kenvue, and previously Johnson & Johnson, failed to adequately warn consumers about these potential risks. The appeals court's decision now paves the way for these cases to proceed, potentially leading to extensive and costly litigation for Kenvue.
This legal setback comes at a sensitive time for Kenvue, which became an independent entity in 2023. While the company has been working to establish its market presence and solidify its portfolio of well-known consumer brands, the shadow of these revived lawsuits could introduce considerable uncertainty for investors. The initial dismissal had provided some relief, but the latest ruling reintroduces a significant legal and financial risk.
The scientific community remains divided on the definitive link between prenatal acetaminophen exposure and autism. While some studies have suggested a correlation, others have found no conclusive evidence. The legal process will now likely involve a deeper examination of the scientific data and expert testimonies, which will be crucial in determining the outcomes of these numerous individual lawsuits.
For Kenvue, the immediate impact has been felt in its share price, reflecting investor concern over potential liabilities and legal expenses. The company has maintained that its products are safe when used as directed and is expected to vigorously defend itself against these claims. The unfolding legal battle will be closely watched by the pharmaceutical and consumer health industries, given the widespread use of acetaminophen-based products globally.